Stromedix Receives Orphan Drug Designation For STX-100 In Chronic Allograft Nephropathy

 23.08.2008 10:31   medicalnewstoday.com

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the US Food and Drug Administration ("FDA") for the treatment of chronic allograft nephropathy. Chronic allograft nephropathy (CAN), also known as chronic allograft dysfunction, is a fibrotic condition that is a leading cause of kidney transplant failure.

World Transplantation